Oragenics, Sterling Pharma Solutions Ink Manufacturing Deal for Concussion Drug
Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion.
Neurological Disorders | 18/07/2025 | By Dineshwori | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy